Early-stage bio-pharma research suffers from complex legal agreements, missing transparency, and reduced investments. This leads to potentially promising research projects all too often being abandoned before they get off the ground. Academia has termed the problem of missing funds between fundamental research and clinical trial "the valley of death".
Molecule aims to solve the "valley of death" by standardizing legal agreements and creating public and liquid markets for funding early-stage research projects. With the advent of decentralised ledger technology (e.g. Ethereum), the creation and management of financial assets have become easier than ever.
Via Molecule, researchers can offer different legal agreements for assets originating from their research (IP, royalty rights, etc.) and collect the funding they need. Investors can easily fund research and provide the funds in an instant given the integration of cryptocurrencies.
You can find a good entry-level blog post on this on Medium: